Navigation Links
New chimeric mouse model for human liver diseases, drug testing
Date:12/4/2007

La Jolla, CA Cells cultured in the lab are like a fish out of water. Often, their behavior does not reflect their biological function within an entire organ or organism, which, for example, turns studying human liver cells into a big challenge.

One way to get around the altered properties of the stranded cells is to populate mouse livers with human hepatocytes in the hope of creating a natural environment, which is exactly what researchers at the Salk Institute for Biological Studies did. They developed a simple system that allows them to transplant human hepatocytes into immunodeficient mice, which can now be used to test how drugs affect the liver.

Rodents are often used as model organisms to study the efficacy and toxicity of drugs, says lead author Karl-Dimiter Bissig, M.D. Ph.D., a postdoctoral researcher in the Laboratory of Genetics, but mouse and rat hepatocytes may function in very different ways when it comes to metabolism of drugs.

In the past, this has led to unexpected toxicity problems, when drugs moved into clinical trials after toxicity tests in rats failed to reveal adverse effects (e.g. Troglitazone). But it also worked the other way around. The clinical introduction of furosamide, a powerful but perfectly safe diuretic, has been slowed down because of its hepatotoxicity in rats, says Bissig.

The work, which will be published in this weeks online edition of the Proceedings of the National Academy of Sciences also holds promise for a better understanding of infectious diseases that affect the liver. It is basically impossible to grow human hepatocytes in the lab, which was a big hurdle for the study of viruses such as hepatitis A and hepatitis B, says senior author Inder Verma, Ph.D., a professor in the Laboratory of Genetics.

But most importantly, Bissig says, the mice will be an invaluable tool to advance regenerative medicine. Many inherited disorders affecting liver metabolism could be cured if only five percent of all hepatocytes would express the missing enzyme, he says.

In fact, thats the underlying principle of the Salk researchers new chimeric mouse. It is based on a murine model for hereditary tyrosinaemia type I, developed by researchers at Oregon Healthy & Science University. An enzymatic defect in the tyrosine catabolism results in a toxic accumulation of byproducts within hepatocytes unless the mice are treated with a drug called NBTC.

Withdrawing the drug allows to selectively expand hepatocytes that do not have this defect, such as transplanted human hepatocytes. Within three months of transplantation, up to 20 percent of the mouse liver is repopulated by human hepatocytes. But whats more, the transplanted cells keep producing a foreign protein slipped inside with the help of a lentiviral vector, the kind usually used for gene therapy. We are very excited about that aspect since very often cells shut off the production of proteins introduced as part of gene therapy, says Verma.


'/>"/>

Contact: Gina Kirchweger
kirchweger@salk.edu
858-453-4100 x1340
Salk Institute  
Source:Eurekalert

Related biology news :

1. A computer for your mouse!
2. Immune cells promote blood vessel formation in mouse endometriosis
3. Cancer-resistant mouse discovered
4. Looking through the eyes of a mouse, scientists monitor circulating cells in its bloodstream
5. Novel 3-D cell culture model shows selective tumor uptake of nanoparticles
6. A new kind of rat model
7. JILA finds flaw in model describing DNA elasticity
8. Smithsonian researchers develop models to assess wetland health
9. Prediction of RNA pseudoknots using heuristic modeling with mapping and sequential folding
10. Simulating kernel production influences maize model accuracy
11. MIT model could improve some drugs effectiveness
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
New chimeric mouse model for human liver diseases, drug testing
(Date:4/17/2017)... April 17, 2017 NXT-ID, Inc. (NASDAQ: ... the filing of its 2016 Annual Report on Form 10-K on ... ... is available in the Investor Relations section of the Company,s website ... SEC,s website at http://www.sec.gov . 2016 Year Highlights: ...
(Date:4/11/2017)... GARDENS, Fla. , April 11, 2017 /PRNewswire/ ... management and secure authentication solutions, today announced that ... by Intelligence Advanced Research Projects Activity (IARPA) to ... IARPA,s Thor program. "Innovation has been ... and IARPA,s Thor program will allow us to ...
(Date:4/11/2017)... -- NXT-ID, Inc. (NASDAQ:   NXTD ) ("NXT-ID" ... of independent Directors Mr. Robin D. Richards and ... furthering the company,s corporate governance and expertise. ... Gino Pereira , Chief Executive Officer ... guidance and benefiting from their considerable expertise as we move ...
Breaking Biology News(10 mins):
(Date:10/12/2017)... ... October 12, 2017 , ... ... platform specifically designed for life science researchers to analyze and interpret datasets, ... Franklin, who made a major contribution to the discovery of the double-helix ...
(Date:10/11/2017)... ... 11, 2017 , ... Personal eye wash is a basic first aid supply for any work ... which eye do you rinse first if a dangerous substance enters both eyes? It’s one ... with its unique dual eye piece. , “Whether its dirt and debris, or an ...
(Date:10/11/2017)... INDIANAPOLIS , Oct. 11, 2017  VMS BioMarketing, a ... of a nationwide oncology Clinical Nurse Educator (CNE) network, which ... growing need for communication among health care professionals to enhance ... physicians, nurses, office staff, and other health care professionals to ... for breast cancer. ...
(Date:10/11/2017)... Austin, TX (PRWEB) , ... October 11, 2017 ... ... in August compared the implantation and pregnancy rates in frozen and fresh ... the contribution of progesterone and maternal age to IVF success. , After comparing ...
Breaking Biology Technology: